Exchange: NASDAQ·Updated 07:30 PM EDT

TRAX First Tracks Biotherapeutics Inc.

$31.85
$0.16
(0.50%)
Today
Closed $31.85
$0.00
(0.00%)
After Hours
Mkt Cap$1.14B
Vol855,242.00

About TRAX

First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.
62

Bullish Sentiment

How do you feel about TRAX?

Quantumup
Canaccord Genuity🏁 $TRAX and said -- We are initiating coverage of First Tracks Biotherapeutics with a BUY rating and 12-month price target of $50. $ANAB ENTO FBRX TAK SNY TEVA $EPRX AZN BMY PHAT ABBV GILD REGN PFE LLY Canaccord Genuity added—The company, a spin-off from AnaptysBio, has three clinical- stage assets: ANB033, rosnilimab, and ANB101. ANB033 accounts for approximately 95% of our assigned value and is currently being evaluated in two Phase Ib trials, with top-line data expected in celiac disease (CeD) in 4Q26 and 1Q27 and in eosinophilic esophagitis (EoE) in 3Q27. The remaining 5% of our valuation comes from rosnilimab, which recently reported positive Phase IIb data in rheumatoid arthritis but is paused pending a partner for Phase III development.

Advertisement|Remove ads.